粘附分子sICAM-1,sVCAM-1,sCD44在高白细胞急性髓系白血病中的表达

Clinical Significance of Cell Adhesion Molecules sICAM-1, sVCAM-1 and sCD44 Expressions in Hyperleukocytic AML

目的探讨高白细胞急性髓系白血病(hyperleukocytic acute myeloid leukemia,HAML)患者治疗前后血清可溶性细胞间粘附分子-1(sICAM-1)、可溶性血管细胞粘附分子(sVCAM-1)和可溶性CD44分子(sCD44)的表达水平及其临床意义。方法采用酶联免疫吸附实验(ELISA),对15例初诊高白细胞急性髓系白血病(WBC>100×109/L)和40例非高白细胞急性髓系白血病(non-hyperleukocytic acute myeloid leukemia,NHAML)(WBC<100×109/L)患者治疗前后的血清sICAM-1、sVCAM-1和sCD44水平进行检测并与正常人比较。结果①HAML组及NHAML组患者化疗前血清的sICAM-1、sVCAM-1和sCD44水平均显著高于对照组,差异有统计学意义,化疗后,两组中骨髓达到缓解者sICAM-1、sVCAM-1和sCD44水平下降,与治疗前比较差异有统计学意义,与对照组比较,差异无统计学意义;②化疗前,HAML组患者血清的sICAM-1、sVCAM-1和sCD44水平显著高于NHAML组患者血清的水平(<0.05),HAML组缓解率40%低于NHAML组缓解率72.5%(<0.05)。结论对于HAML患者,检测血清sICAM-1、sVCAM-1和sCD44水平,有助于指导临床治疗,为病情监测、疗效观察及预后判定提供了有价值的临床指标。

Objective Discussion on hyperleukocytic acute myeloid leukemia(HAML)before and after treatment in patients with serum soluble intercellular adhesion molecule-1(sICAM-1),soluble vascular celladhesion molecule-1(sVCAM-1)and soluble CD44 molecule(sCD44)expression level and its clinical significance.Methods By using enzyme linked immunosorbent assay(ELISA),were detected in 15 patients with HAML(WBC>100í109/L)and 40 patients with non-hyperleukocytic acute myeloid leukemia(NHAML,WBC<100í109/L)before and after treatment the serum sICAM-1,sVCAM-1 and sCD44 levels,and compared with the normal people.Results①Before chemotherapy,NAML and NHAML patient serum sICAM-1,sVCAM-1 and sCD44 levels were significantly higher than those in the control group,the difference has statistical significance.After chemotherapy,in the two groups to achieve remission of bone marrow sICAM-1,sVCAM-1 and sCD44 levels decreased,compared with before treatment was statistical y significant;Compared with the control group,no significant difference.②Before chemotherapy,HAML patients serum sICAM-1,sVCAM-1 and sCD44 levels were significantly higher than those in NHAML patients with serum sICAM-1,sVCAM-1 and sCD44 level(<0.05),HAML patients remission rate(40%)was lower than NHAML patients remission rate(72.5%)(<0.05).Conclusion For patients with HAML,detection of serum sICAM-1,sVCAM-1 and sCD44 levels,help to guide the clinical treatment,provides valuable clinical indicators for monitoring,curative effect observation and prognosis.